Search
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalIt is available as oral tablets under the market name GEMTESA. … Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity.
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalPGX-100 is an intravenous dosage form of modified heparin. … It is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity.
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigational[L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory
Synonyms: human cytomegalovirus (CMV) promoter and terminated with a 3' untranslated region and a simian virus 40 (SV40) polyadenylation signal, gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteins under control of aNefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnDrug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to … Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb.
Synonyms: 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-oneTonapofylline
go.drugbank.com/drugs/DB12569InvestigationalTonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.
Categories: Receptor, Adenosine A1Tegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawna lower risk of a cardiovascular event than the broader population. … cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and whom are considered to be at
Pentobarbital
go.drugbank.com/drugs/DB00312ApprovedVet approvedA short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. … (From AMA Drug Evaluations Annual, 1994, p236)
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5. … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Romiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalEach subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. … Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor.